The Plant That Never Got Its Trial

At Horizons in New York in 2014, I opened a talk on Salvia divinorum with a show of hands. Most of the room had heard of salvia. When I asked who knew its Indigenous lineage, the Mazatec curanderas of Oaxaca who have worked with it for generations, almost no hands went up. Then I asked who knew the Indigenous lineage of ayahuasca. Nearly every hand in the room. I left that gap hanging, because I didn't have a clean answer and still don't. Why does a clinician audience know salvia only through grainy phone footage of a teenager sliding off a couch, while ayahuasca arrives wrapped in its cultural context? (The conference recording cut that opening, for reasons I never learned. So here it is in writing.)

The gap is worth sitting with, because it points at something true about the whole field. Salvia divinorum is genuinely psychoactive. It has a real, traceable ceremonial tradition. And it never became a therapy, or even a respectable research subject, the way psilocybin and MDMA did. That outcome was not handed down by the science. The science barely got to start.

The active compound, salvinorin A, is a selective and potent agonist at the kappa-opioid receptor (KOR). That single fact sets it apart from nearly everything else in the psychedelic conversation. Psilocybin, LSD, and DMT act primarily at the **5-HT2A serotonin receptor**. Salvinorin A does not. It is the most potent naturally occurring psychoactive compound we know of, and it works through an entirely different door.

That pharmacology produces a very specific experience. Smoked, the effects come on in seconds and resolve in roughly eight to fifteen minutes. The state is intensely dissociative and disorienting rather than euphoric, and for many people it tips into outright dysphoria. Because salvinorin A does not touch the mu-opioid receptor, it does not carry the classic opioid profile of respiratory depression or physiological dependence.

The preclinical literature is genuinely interesting. Low-dose KOR agonism shows antidepressant and anxiolytic signals in animal models, reduced drug-reward responses in addiction paradigms, and neuroprotective effects. But every one of those findings is preclinical. As the Calado review states plainly, rigorous placebo-controlled human therapeutic trials remain scarce to nonexistent. Nothing here has been shown in patients. A clinician who reads "antidepressant" in a headline and a clinician who reads it in an animal study are reading two different claims.

Salvia divinorum is bound to the Mazatec people of the Sierra Mazateca in Oaxaca, Mexico, where it is known as Ská Pastora, the leaves of the shepherdess, tied to the same curandera lineage made famous in the West by María Sabina. In that context the plant is used at low dose, the fresh leaves chewed or taken sublingually as a quid, inside a divinatory and ritual frame held by a healer.

The tradition is also more clinically specific than most Western readers assume. Years ago I co-wrote a piece for Scientific American with Ana Elda Maqueda on Mazatec healers using the plant to treat addictions to alcohol, inhalants, and stimulants. The anti-addiction signal the preclinical literature is now chasing is something those healers described in their own framework long before a KOR assay existed.

That bears almost no resemblance to the Western pattern, which is a high-dose concentrated extract smoked alone for novelty. Same plant, two worlds. Naming that difference is not decoration. When a tradition's knowledge gets stripped down to a viral clip, the people who preserved it disappear from the story, and what's left looks like a drug instead of a practice. Cultural humility here means knowing whose knowledge this is and resisting the urge to extract the molecule from the people.

Two forces explain the empty trial registry, and only one of them is scientific.

The pharmacology is a genuine obstacle. A dysphoric, profoundly disorienting state that lasts eight minutes does not fit the assisted-therapy model, which depends on a workable window for preparation, relationship, and processing. You cannot do the therapy inside that window.

The other force is structural, and it is the one I'd ask you to hold. There is no patent on a plant, the smoked experience is brief and unpleasant rather than marketable, and there is no revenue model in any of it. So the money went elsewhere. The 2026 Nature Communications genome paper that finally mapped salvinorin A's biosynthetic pathway states its own motivation directly: the interest is in developing patentable pain, anti-addiction, and antidepressant medications built on the molecule's KOR selectivity. The industry wants the receptor, not the plant. That is a choice about capital, not a verdict from the data. The market decides what gets studied, and salvia is a clean illustration of what the market skips.

A client will eventually mention salvia, often because it is legal and available where a regulated psychedelic is not. A few things are worth having ready.

• Legality is a patchwork. Status varies by state and changes. Point the client to verified current law, and route any legal-exposure question to the appropriate resource. For your own scope, consult your state licensing board rather than offering a legal opinion.
• The risk that matters most is physical. During the active window a person can fall, walk into things, or injure themselves while disconnected from their surroundings. Set and setting are not optional add-ons here; a sitter and a safe space are basic harm reduction.
• The experience is not casual. Brief does not mean mild. This is one of the more disorienting states a person can enter, and it deserves to be treated seriously rather than as a dare.

The deeper point is the one I left hanging in that room in 2014. We know the substances the market chose to develop, and we know them in the polished language of clinical promise. The ones it skipped, we know as YouTube footage or not at all. That asymmetry is not a fact of nature. It is a fact of who pays for research, and it is worth noticing every time a client asks why the plant nobody studied is the one they can buy.

Salvia divinorum is a psychoactive plant from Oaxaca, Mexico, traditionally used by Mazatec healers. Its active compound, salvinorin A, is the most potent naturally occurring psychoactive substance known and acts on the kappa-opioid receptor, not the serotonin 5-HT2A receptor that psilocybin and LSD use. That makes its effects pharmacologically distinct from classic psychedelics.

Salvinorin A does not act on the mu-opioid receptor, so it does not cause the respiratory depression or dependence associated with opioids. The main risk is physical: during the brief, intensely dissociative window a person can fall or injure themselves while disconnected from their surroundings. A sober sitter and a safe space are basic harm reduction.

It depends on the state. Salvia's legal status is a patchwork that varies by jurisdiction and changes over time, and it is not a clinician's role to adjudicate it. Point clients to verified current law for their state, and route legal-exposure questions to an appropriate resource. For your own scope, consult your licensing board.

Not based on current evidence. Low-dose kappa-opioid agonism shows antidepressant, anti-addiction, and neuroprotective signals, but every one of those findings is preclinical, mostly in animal models. There are no rigorous placebo-controlled human therapeutic trials. Tell clients directly that the promising headlines describe lab findings, not demonstrated treatment in patients.

Peter Addy, PhD, LPC, LMHC is a Portland-based licensed therapist and the founder of Psychedelic Affirming Education, an NBCC-approved continuing education provider for licensed mental health professionals and Oregon Psilocybin Services facilitators. He presented on Salvia divinorum at Horizons NYC (2014) and Psychedelic Science (2017), and his research background includes work at Yale School of Medicine on psychedelic substances.

Want the clinician's view on the research the headlines skip? Sign up for the newsletter below. I write for working therapists about the science, the politics, and the practice of this field, without the hype.

When a client tells you they've used salvia, ketamine, or any other substance on their own, the work is in what comes next. Our free guide walks through it.